The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein Listen: Lilly’s obesity drug, the power of radiation, & a biotech implosion
The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein Listen: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO
The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein Listen: ESMO highlights, Roivant’s big deal, & biotech VC on the rise
The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein Listen: Live from the 2023 STAT Summit
The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein Listen: Merger Mondays, Ozempic panic, & CRISPR’d pigs
The Readout LOUD Damian Garde and Allison DeAngelis Listen: Who discovered GLP-1? Plus: BrainStorm at the FDA and biotech’s slump
The Readout LOUD Damian Garde and Allison DeAngelis A thorny ALS debate at the FDA, and the promise of artificial wombs
The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein Listen: Covid’s latest surge, Alnylam at the FDA, & the end of an era
The Readout LOUD Damian Garde and Adam Feuerstein Back to school for biotech, Biogen’s potential pivot, & Illumina’s next chapter
The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein Listen: Vivek’s star turn, leaky drug data, & biotech as family business
The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein Listen: Racing for gene therapy, a pioneering approval, & startups in the lurch
The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein Listen: Your guide to Wegovy’s blockbuster heart study
The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein Listen: Biotech layoffs, eye drug drama, & gene therapy milestones
The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein Biogen’s sticky situation, Wegovy’s risks, & biotech insider trading
The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein BridgeBio’s big week, Lilly’s Alzheimer’s data, & succession at Stanford
The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein Listen: Wegovy in the brain, pivotal Alzheimer’s data, & pulling Threads
The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein Listen: Novavax’s CEO promises a turnaround & how Lilly roiled the obesity market
The Readout LOUD Damian Garde and Meg Tirrell Listen: Messy PBM conflicts, debatable vaccines, & the future of flu season
The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein Listen: Biogen’s messy board, Laronde’s data problem, & the downside of a boom
The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA
The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein Listen: Fake medical devices, real cancer drugs, & curious Ozempic effects
The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein Listen: ChatGPT in medicine, a boom in weight loss pills, & Sarepta at the FDA
The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein Listen: The FTC v. Amgen, Sarepta’s future, & Galapagos’ turnaround
The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein Listen: Pharma vs. PBMs, Sarepta at the FDA, & a bold idea gone awry
The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein Listen: Lilly’s Alzheimer’s success, a milestone FDA approval, & Moderna’s shrinking business
The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein Listen: Explaining the E.U.’s pharma overhaul, Lilly’s booming business, & a long-awaited drug approval
The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein Listen: Sarepta’s pivotal moment, biotech’s big week, & the future of Covid boosters
The Readout LOUD Damian Garde and Meg Tirrell Listen: How the legal battle over abortion could thwart research, plus: the FDA ‘bully pulpit’ and Moderna’s future
The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein Listen: Illumina’s boardroom intrigue, the next big Alzheimer’s readout, & J&J’s creative lawyers